Hypofractionated Radiation Therapy for Breast Cancer

Recruiting in Palo Alto (17 mi)

Dr. Shane R Stecklein, MD, PhD - Kansas ...

Overseen byShane Stecklein, MD, PhD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Kansas Medical Center

No Placebo Group

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?The primary objective of this study is to document lymphedema rates in patients requiring regional nodal irradiation (RNI) who receive hypofractionated radiation as compared to conventional radiation.

Eligibility Criteria

This trial is for women with certain stages of breast cancer who may be of child-bearing age and agree to use contraception. They should have had prior surgery or chemotherapy but no radiation in the target area, and their physical condition must allow them to participate actively in daily life.

Inclusion Criteria

I have a specific type of cancer with certain high-risk features.

I agree to use effective birth control or abstain from sex during and for 90 days after the study.

I can perform most of my daily activities without assistance.

+2 more

Exclusion Criteria

I have been cancer-free for over 5 years, except for skin cancer.

I have been diagnosed with lupus.

My cancer has spread to other parts of my body.

+4 more

Participant Groups

The study is testing hypofractionated radiation therapy compared to conventional radiation, specifically looking at lymphedema rates (swelling due to fluid build-up) among patients needing regional nodal irradiation.

1Treatment groups

Experimental Treatment

Group I: Hypofractionated Radiation TherapyExperimental Treatment1 Intervention

Daily for 4 weeks

Hypofractionated Radiation Therapy is already approved in United States, European Union, Canada for the following indications:

🇺🇸 Approved in United States as Hypofractionated Radiotherapy for: